National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Neuroblastoma Screening (PDQ®)
Patient VersionHealth Professional VersionLast Modified: 06/21/2005



Overview of Screening







Neuroblastoma Screening






Get More Information From NCI






Changes to This Summary (06/21/2005)






Questions or Comments About This Summary






About PDQ



Page Options
Print This Page  Print This Page
Print This Document  Print Entire Document
View Entire Document  View Entire Document
E-Mail This Document  E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate

New Study of Targeted Therapies for Breast Cancer

The Nation's Investment in Cancer Research FY 2009

Cancer Trends Progress Report: 2007 Update

Past Highlights
You CAN Quit Smoking Now!
Neuroblastoma Screening

Risk of neuroblastoma
Screening tests for neuroblastoma

Neuroblastoma is a cancer that primarily affects children. It begins in nerve tissue in the neck, chest, abdomen, or pelvis. It usually originates in the abdomen in the tissues of the adrenal gland. By the time it is diagnosed, the cancer often has spread, most commonly to the lymph nodes, liver, lungs, bones, and/or bone marrow.

Risk of neuroblastoma

Neuroblastoma is the most common type of cancer in infants. The number of new cases of neuroblastoma is greatest among children under 1 year of age and decreases rapidly with age. Males are affected slightly more commonly than females.

Anything that increases a person’s chance of developing a disease is called a risk factor. The risk factors for neuroblastoma have not yet been established.

Screening tests for neuroblastoma

Urine samples can be tested for the presence of specific chemicals that are excreted by most patients with neuroblastoma. Most cases of neuroblastoma are diagnosed before 6 months of age.

It is thought that many neuroblastomas are present and detectable at birth. Studies have suggested devising a once-in-a-lifetime screening test, such as those used for screening newborns for noncancerous conditions, such as phenylketonuria. At this time, however, there is no good scientific evidence showing that screening for neuroblastoma leads to a decrease in deaths from the disease.

Back to TopBack to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov